Industry Insights
Deep dives on clinical endpoints, regulatory trends and data quality — written and curated by the EClinCloud team.
How Many Systems Does Your First Trial Need? A Registry-Derived eClinical Module Map for Small Sponsors (2026)A protocol-based guide to the records, workflows and eClinical capabilities needed for a first regulated clinical trial.
Medical Device Clinical Investigations in 2026: What ISO 14155, IDE Studies and EU MDR Annex XV Demand From EDC, eCOA and Site OversightCompare device trial records, FDA inspection observations and ISO 14155 edition references to configure device safety, accountability and monitoring.
Multiregional Clinical Trials With China Sites in 2026: HGR Approval, PIPL Data Export and What the Registries ShowMap HGR, personal-information exports and hosting decisions for China-inclusive multiregional trials, with bounded registry evidence and practical regulatory checks.
Clinical Trial Rater Training 2026: Certification, Inter-Rater Reliability and Drift Monitoring for CNS ClinRO EndpointsA risk-based framework for CNS clinical trial rater training, certification, reliability and drift controls, grounded in registry and regulatory evidence.
Clinical Outcome Instruments: From Registry Names to CDISC QRS and Study-Build DecisionsWhat 299,607 registered studies reveal about instrument wording, CDISC QRS and NIH CDE discovery, with a study-build checklist.
BICR in Oncology Trials: What Registry Wording and FDA/EMA Evidence Can Tell YouAudit of 22,772 registry records, FDA and EMA guidance, and eight review studies, with a practical imaging-charter checklist.
FDA Investigator Records and Site Monitoring: What BMIS and Inspection Data Can SupportAn independently recomputed BMIS record audit, FDA inspection evidence and study-location analysis for site qualification and monitoring decisions.
eCOA Linguistic Validation 2026: Translate, Adapt, License or Revalidate for a Multinational Trial?A cell-based framework for licensing, translating, adapting or validating eCOA versions across languages, populations, modes and contexts of use.
CTIS Trial Results Disclosure 2026: Summary Results, Layperson Summaries and Clinical Study Reports — What Sponsors Must Prepare and WhenA sponsor workpaper for CTIS results disclosure: map the applicable clock, separate secure submission from public publication, and control each artifact.
RTSM Trial Supply Planning 2026: How to Turn Registry Flags into a Protocol-Level Supply DecisionA protocol-level framework for deciding when randomized drug trials need RTSM, using registry flags as triage—not as a substitute for supply-chain facts.
Clinical Trial Protocol Complexity 2026: Endpoints, Multicenter Countries and Study-Build Workload on ClinicalTrials.govPublic protocol files store outcome, group, country and facility multipliers, not EDC hours. Median studies are small; Phase 3 industry interventional trials sit on a different build surface.
FDA PFDD Guidance 3 and ClinicalTrials.gov 2026: PRO vs ClinRO Tokens, Patient-Reported Outcome Registration, and eCOA ImplementationFDA PFDD Guidance 3 is a fit-for-purpose selection file. ClinicalTrials.gov outcome text almost never stores COA type; PRO language is common and still not validation.